BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 31610670)

  • 1. Lymphangioleiomyomatosis.
    Doubková M; Štefániková M; Čan V; Merta Z; Svoboda M
    Klin Onkol; 2019; 32(5):367-374. PubMed ID: 31610670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pulmonary lymphangioleiomyomatosis. A study of 69 patients. Groupe d'Etudes et de Recherche sur les Maladies "Orphelines" Pulmonaires (GERM"O"P).
    Urban T; Lazor R; Lacronique J; Murris M; Labrune S; Valeyre D; Cordier JF
    Medicine (Baltimore); 1999 Sep; 78(5):321-37. PubMed ID: 10499073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus.
    Taveira-DaSilva AM; Hathaway O; Stylianou M; Moss J
    Ann Intern Med; 2011 Jun; 154(12):797-805, W-292-3. PubMed ID: 21690594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of sirolimus in lymphangioleiomyomatosis.
    McCormack FX; Inoue Y; Moss J; Singer LG; Strange C; Nakata K; Barker AF; Chapman JT; Brantly ML; Stocks JM; Brown KK; Lynch JP; Goldberg HJ; Young LR; Kinder BW; Downey GP; Sullivan EJ; Colby TV; McKay RT; Cohen MM; Korbee L; Taveira-DaSilva AM; Lee HS; Krischer JP; Trapnell BC; ;
    N Engl J Med; 2011 Apr; 364(17):1595-606. PubMed ID: 21410393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Should mammalian target of rapamycin inhibitors be stopped in women with lymphangioleiomyomatosis awaiting lung transplantation?
    El-Chemaly S; Goldberg HJ; Glanville AR
    Expert Rev Respir Med; 2014 Dec; 8(6):657-60. PubMed ID: 25199529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resolution of Thoracic and Abdominal Lymphangioleiomyomas in a Patient With Lymphangioleiomyomatosis Treated With Sirolimus.
    Cabeza Osorio L; Ruiz Cobos MÁ; Casanova Espinosa Á
    Arch Bronconeumol; 2016 Jun; 52(6):329-30. PubMed ID: 25912780
    [No Abstract]   [Full Text] [Related]  

  • 7. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis.
    Bissler JJ; McCormack FX; Young LR; Elwing JM; Chuck G; Leonard JM; Schmithorst VJ; Laor T; Brody AS; Bean J; Salisbury S; Franz DN
    N Engl J Med; 2008 Jan; 358(2):140-51. PubMed ID: 18184959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative CT predicts the severity of physiologic dysfunction in patients with lymphangioleiomyomatosis.
    Crausman RS; Lynch DA; Mortenson RL; King TE; Irvin CG; Hale VA; Newell JD
    Chest; 1996 Jan; 109(1):131-7. PubMed ID: 8549175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and histopathological alterations of lymphangioleiomyomatosis in 14 Chinese patients.
    Lu SH; Hou YY; Tan YS; Xu JF; Zeng HY; Sujie AK; Wang XD; Bai CX
    Chin Med J (Engl); 2009 Aug; 122(16):1895-900. PubMed ID: 19781367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. mTOR treatment in lymphangioleiomyomatosis: the role of everolimus.
    Yates DH
    Expert Rev Respir Med; 2016; 10(3):249-60. PubMed ID: 26847859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of beta-agonists on LAM progression and treatment.
    Le K; Steagall WK; Stylianou M; Pacheco-Rodriguez G; Darling TN; Vaughan M; Moss J
    Proc Natl Acad Sci U S A; 2018 Jan; 115(5):E944-E953. PubMed ID: 29339522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lymphangioleiomyomatosis in patients with tuberous sclerosis: a national centre audit.
    Johnson J; Somerfield W; Johnson SR
    Orphanet J Rare Dis; 2024 Mar; 19(1):137. PubMed ID: 38532450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy and adverse events of mTOR inhibitors in lymphangioleiomyomatosis: systematic review and meta-analysis.
    Gao N; Zhang T; Ji J; Xu KF; Tian X
    Orphanet J Rare Dis; 2018 Aug; 13(1):134. PubMed ID: 30107845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of transbronchial lung biopsy for the diagnosis of lymphangioleiomyomatosis: A report of 24 consecutive patients.
    Koba T; Arai T; Kitaichi M; Kasai T; Hirose M; Tachibana K; Sugimoto C; Akira M; Hayashi S; Inoue Y
    Respirology; 2018 Mar; 23(3):331-338. PubMed ID: 28960664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Lymphangioleiomyomatosis].
    Wirtz H
    Zentralbl Chir; 2013 Oct; 138 Suppl 1():S59-74; quiz 75-6. PubMed ID: 24277558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical analysis of lymphangioleiomyomatosis].
    Gao P; Huang R; Cai BQ; Liu HR
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Jun; 26(3):306-9. PubMed ID: 15266836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging clinical picture of lymphangioleiomyomatosis.
    Cohen MM; Pollock-BarZiv S; Johnson SR
    Thorax; 2005 Oct; 60(10):875-9. PubMed ID: 16055626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COPD assessment test as a possible tool for evaluating health-related quality of life in lymphangioleiomyomatosis.
    Kato M; Kanehiro Y; Yoshimi K; Kodama Y; Sekiya M; Sato T; Takahashi K; Seyama K;
    Respir Investig; 2018 Nov; 56(6):480-488. PubMed ID: 30143460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lymphangioleiomyomatosis.
    Taveira-DaSilva AM; Steagall WK; Moss J
    Cancer Control; 2006 Oct; 13(4):276-85. PubMed ID: 17075565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lymphangioleiomyomatosis: a clinical update.
    McCormack FX
    Chest; 2008 Feb; 133(2):507-16. PubMed ID: 18252917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.